I’m a senior PM at a B2B SaaS company trying to figure out the cleanest bridge into VC. I’ve got a few solid wins (pricing revamp that improved payback, a churn fix that moved net retention, and a platform partnership that opened a new motion), but I’m not sure which path actually converts those into “VC signals.” I’m weighing three routes over the next 12 months: jump to corp dev for transaction exposure, try to land a founder-in-residence slot, or stay PM and build a visible thesis + scout deals. For folks who’ve sat on the other side of the table: which path signals strongest, and what artifacts (memos, references, theses) made the difference? If you’ve made the jump, which path actually moved the needle, and how did you frame your PM wins so partners cared?
fir isn’t a cheat code; it only works if the fund already wants you. corp dev is a different sport — you’ll do integration checklists, not “pattern matching.” if you want vc, build angles now: scout a few checks, write memos, get founders to vouch. translate your pm wins into market wedges, unit economics, and sales efficiency stories. pick a stage and commit. pre-seed cares about founder empathy; growth cares about retention, payback, net dollar expansion. timeline? 6–12 months of consistent deal flow beats another launch press release.
staying pm can work if you become the “deals” pm — source partnerships, run real diligence calls, write tight postmortems. get a partner or two to say you’re useful. corp dev titles lull you into thinking you’re close to vc; you’re not, you’re close to procurement. fir without a thesis is paid navel-gazing. choose the route where an actual investor will pick up the phone and say, “this person helped us win a deal,” not “nice roadmap.”
quick thought
i’m junior pm too. does corp dev teach real deal judgment or just model cleanup? i’m leaning to stay pm and publish mini-theses + scout 1-2 checks. seems more visible? curious what worked for folks here.
fwiw
saw a pm get interviews after public teardown threads + founder refs. fir felt hard w/out brand. maybe ship 2 memos/month and track sourced deals? anyone confirm this works?
Each path signals something different. Corp dev demonstrates transaction hygiene, stakeholder wrangling, and exposure to acquisition logic, but you’ll need to prove you can source and form a thesis beyond a buyer’s lens. Founder-in-residence signals founder empathy and zero-to-one thinking, but only if it results in tangible artifacts: memos, early diligence wins, and credible founder references. Remaining in PM can be powerful if you make your investing muscle visible: a consistent pipeline, structured memos, and measurable contributions to a fund’s sourcing or diligence. Time-box it. Set 90 days to publish stage-specific theses, source five qualified companies, run two full diligence sprints, and collect one partner-caliber reference. Choose the lane where you can produce those outputs fastest with authentic leverage.
I tried the corp dev detour first. Learned a ton about integration risk, but felt far from sourcing. Switched to a tiny FiR stint with a seed fund. I wrote five memos, helped diligence two deals, and introduced one founder they actually backed. That, plus a few candid founder references, got me associate interviews. What moved the needle: a consistent weekly cadence and artifacts I could send cold. PM wins mattered once I translated them into market insight and payback narratives, not feature ships.
Pick the route that maximizes visible output. In 12 weeks, aim to publish two stage-specific theses, source 10–15 companies with clear filtering logic, and run two full diligence write-ups including retention, payback period, and sales efficiency analysis. From PM wins, quantify impact as investor-friendly metrics: net dollar retention shifts, CAC payback improvements, attach rate increases, and cohort curves. If you choose corp dev, ensure you can speak to sourcing and thesis development, not just execution. If FiR, set targets for memo cadence and founder references. Track everything in a simple CRM and share selectively with investors.